BVT 115959

Drug Profile

BVT 115959

Alternative Names: BVT.115959; CBT-1008

Latest Information Update: 24 Feb 2010

Price : $50

At a glance

  • Originator Cambridge Biotechnology
  • Developer Swedish Orphan Biovitrum
  • Class Analgesics
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammatory pain; Neuropathic pain

Most Recent Events

  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
  • 07 Apr 2008 Efficacy data from a phase II trial in Neuropathic pain released by Biovitrum
  • 14 Dec 2007 Biovitrum completes a phase II trial in Neuropathic pain in the Czech Republic, Germany and South Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top